|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size 2/23/23 Boston Scientific Corp. 10-K 12/31/22 102:22M |
Document/Exhibit Description Pages Size
1: 10-K Annual Report HTML 4.04M
2: EX-10.55 Material Contract HTML 201K
3: EX-10.56 Material Contract HTML 198K
4: EX-10.57 Material Contract HTML 58K
5: EX-10.58 Material Contract HTML 61K
6: EX-10.65 Material Contract HTML 211K
7: EX-10.66 Material Contract HTML 199K
8: EX-10.67 Material Contract HTML 90K
9: EX-10.68 Material Contract HTML 90K
10: EX-10.69 Material Contract HTML 58K
11: EX-10.70 Material Contract HTML 61K
12: EX-10.72 Material Contract HTML 111K
13: EX-10.76 Material Contract HTML 210K
14: EX-10.77 Material Contract HTML 203K
15: EX-10.78 Material Contract HTML 90K
16: EX-10.79 Material Contract HTML 89K
17: EX-10.80 Material Contract HTML 58K
18: EX-10.81 Material Contract HTML 61K
19: EX-10.83 Material Contract HTML 32K
20: EX-10.84 Material Contract HTML 31K
21: EX-10.85 Material Contract HTML 96K
22: EX-21 Subsidiaries List HTML 33K
23: EX-23 Consent of Expert or Counsel HTML 25K
24: EX-31.1 Certification -- §302 - SOA'02 HTML 33K
25: EX-31.2 Certification -- §302 - SOA'02 HTML 33K
26: EX-32.1 Certification -- §906 - SOA'02 HTML 27K
27: EX-32.2 Certification -- §906 - SOA'02 HTML 27K
33: R1 Cover HTML 95K
34: R2 Audit Information HTML 29K
35: R3 Consolidated Statements of Operations HTML 125K
36: R4 Consolidated Statements of Comprehensive Income HTML 52K
(Loss)
37: R5 Consolidated Balance Sheets HTML 136K
38: R6 Consolidated Balance Sheet Paranthetical HTML 40K
39: R7 Consolidated Statements of Stockholders' Equity HTML 104K
40: R8 Consolidated Statements of Cash Flows HTML 148K
41: R9 Consolidated Statements of Cash Flows Consolidated HTML 36K
Statement of Cash Flows (Supplemental Disclosure)
42: R10 Significant Accounting Policies HTML 94K
43: R11 Acquisitions and Strategic Investments HTML 147K
44: R12 Goodwill and Other Intangible Assets HTML 75K
45: R13 Hedging Activities and Fair Value Measurements HTML 243K
46: R14 Contractual Obligations and Commitments HTML 113K
47: R15 Leases HTML 51K
48: R16 Supplemental Balance Sheet Information HTML 111K
49: R17 Income Taxes HTML 146K
50: R18 Commitments and Contingencies HTML 54K
51: R19 Stockholders' Equity HTML 39K
52: R20 Stock Inventive and Purchase Plans HTML 154K
53: R21 Weighted Average Shares Outstanding HTML 44K
54: R22 Segment Reporting HTML 105K
55: R23 Revenue HTML 116K
56: R24 Changes in Other Comprehensive Income HTML 59K
57: R25 New Accounting Pronouncements HTML 36K
58: R26 Employee Retirement Plans (Notes) HTML 119K
59: R27 Schedule II HTML 41K
60: R28 Significant Accounting Policies Significant HTML 144K
Accounting Policies (Policies)
61: R29 Fair Value Measures and Disclosures (Policies) HTML 32K
62: R30 Commitment and Contingencies (Policies) HTML 30K
63: R31 New Accounting Pronouncements (Policies) HTML 44K
64: R32 Employee Retirement Plans Employee Retirement HTML 28K
Plans (Policies)
65: R33 Acquisitions and Strategic Investments (Tables) HTML 143K
66: R34 Goodwill and Other Intangible Assets Goodwill and HTML 74K
Other Intangible Assets (Tables)
67: R35 Hedging Activities and Fair Value Measurements HTML 227K
(Tables)
68: R36 Contractual Obligations and Commitments (Tables) HTML 114K
69: R37 Leases (Tables) HTML 51K
70: R38 Supplemental Balance Sheet Information (Tables) HTML 124K
71: R39 Income Taxes (Tables) HTML 145K
72: R40 Stock Incentive and Purchase Plans (Tables) HTML 155K
73: R41 Weighted Average Shares Outstanding (Tables) HTML 43K
74: R42 Segment Reporting (Tables) HTML 108K
75: R43 Revenue (Tables) HTML 109K
76: R44 Changes in Other Comprehensive Income (Tables) HTML 56K
77: R45 Employee Retirement Plans (Tables) HTML 127K
78: R46 Significant Accounting Policies Significant HTML 33K
Accounting Policies (Details)
79: R47 Acquisitions and Strategic Investments (Details) HTML 253K
80: R48 Contingent Consideration (Details) HTML 71K
81: R49 Strategic Investments (Details) HTML 40K
82: R50 Goodwill and Other Intangible Assets (Details) HTML 83K
83: R51 Fair Value Measurements (Details) HTML 239K
84: R52 Contractual Obligations and Commitments (Details) HTML 236K
85: R53 Leases (Details) HTML 73K
86: R54 Supplemental Balance Sheet Information (Details) HTML 174K
87: R55 Income Taxes (Details - Rate Table) HTML 65K
88: R56 Income Taxes Income Taxes (Details) HTML 178K
89: R57 Commitments and Contingencies (Details) HTML 38K
90: R58 Stockholders' Equity (Details) HTML 83K
91: R59 Stock Incentive and Purchase Plans (Details) HTML 207K
92: R60 Weighted Average Shares Outstanding (Details) HTML 42K
93: R61 Segment Reporting (Details) HTML 111K
94: R62 Revenue (Details) HTML 112K
95: R63 Changes in Other Comprehensive Income (Details) HTML 76K
96: R64 Employee Retirement Plans (Details) HTML 133K
97: R65 Schedule II (Details) HTML 36K
100: XML IDEA XML File -- Filing Summary XML 153K
98: XML XBRL Instance -- bsx-20221231_htm XML 5.24M
99: EXCEL IDEA Workbook of Financial Reports XLSX 272K
29: EX-101.CAL XBRL Calculations -- bsx-20221231_cal XML 205K
30: EX-101.DEF XBRL Definitions -- bsx-20221231_def XML 1.37M
31: EX-101.LAB XBRL Labels -- bsx-20221231_lab XML 2.95M
32: EX-101.PRE XBRL Presentations -- bsx-20221231_pre XML 1.71M
28: EX-101.SCH XBRL Schema -- bsx-20221231 XSD 240K
101: JSON XBRL Instance as JSON Data -- MetaLinks 688± 1.11M
102: ZIP XBRL Zipped Folder -- 0000885725-23-000008-xbrl Zip 1.66M
| Document |
| 1 | I have reviewed this Annual Report on Form 10-K of Boston Scientific Corporation; | |||||||
| 2 | Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; | |||||||
| 3 | Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; | |||||||
| 4 | The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: | |||||||
a) | Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; | |||||||
b) | Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; | |||||||
c) | Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and | |||||||
d) | Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and | |||||||
| 5 | The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions): | |||||||
a) | All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and | |||||||
b) | Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting. | |||||||
| Date: February 23, 2023 | /s/ Michael F. Mahoney | ||||||||||||||||
| Michael F. Mahoney | |||||||||||||||||
| Chief Executive Officer | |||||||||||||||||
| This ‘10-K’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| Filed on: | 2/23/23 | None on these Dates | ||
| For Period end: | 12/31/22 | |||
| List all Filings | ||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 2/23/24 Boston Scientific Corp. 424B2 2:740K Toppan Merrill/FA 2/22/24 Boston Scientific Corp. 424B5 1:704K Toppan Merrill/FA 2/20/24 Boston Scientific Corp. 10-K 12/31/23 90:16M |